Matthew Weston
Stock Analyst at UBS
(4.42)
# 1,211
Out of 4,581 analysts
353
Total ratings
74.6%
Success rate
11.4%
Average return
Main Sectors:
Stocks Rated by Matthew Weston
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SWX: GALD Galderma Group AG | Maintained: Buy | CHF 200.00 | CHF 176.95 | +13.03% | 12 | Jul 24, 2026 | |
| SWX: NOVN Novartis AG | Maintained: Hold | CHF 116.00 | CHF 130.40 | -11.04% | 47 | Jul 22, 2026 | |
| ETR: MRK Merck KGaA | Maintained: Buy | €150.00 | €144.25 | +3.99% | 36 | Jul 20, 2026 | |
| LON: AZN AstraZeneca PLC | Maintained: Buy | 17,600p | 13,108p | +34.27% | 66 | Jul 13, 2026 | |
| LON: GSK GSK plc | Maintained: Hold | 1,940p | 2,018p | -3.87% | 18 | Jul 13, 2026 | |
| ETR: BAYN Bayer Aktiengesellschaft | Maintained: Buy | €52.00 | €47.03 | +10.57% | 22 | Jul 13, 2026 | |
| LON: 0QIU Novo Nordisk A/S | Maintained: Hold | kr 332.00 | kr 330.56 | +0.44% | 27 | Jul 13, 2026 | |
| ETR: SRT3 Sartorius Aktiengesellschaft | Maintained: Hold | €240.00 | €222.40 | +7.91% | 29 | Jul 13, 2026 | |
| EPA: DIM Sartorius Stedim Biotech S.A. | Maintained: Hold | €220.00 | €170.00 | +29.41% | 16 | Jul 13, 2026 | |
| EPA: SAN Sanofi | Maintained: Hold | €88.00 | €79.38 | +10.86% | 15 | Jul 13, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | CHF 376.00 | CHF 367.90 | +2.20% | 55 | May 13, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $125 | $131.82 | n/a | 1 | Nov 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | CHF 750.00 | CHF 560.20 | n/a | 2 | Jan 27, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgraded: Hold | €95.00 → €72.00 | €160.40 | n/a | 3 | Feb 11, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $310 | $50.96 | n/a | 3 | Nov 2, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Sell | n/a | $159.85 | n/a | 1 | Jul 5, 2017 |
Galderma Group AG
Jul 24, 2026
Maintained: Buy
Price Target: CHF 200.00
Current: CHF 176.95
Upside: +13.03%
Novartis AG
Jul 22, 2026
Maintained: Hold
Price Target: CHF 116.00
Current: CHF 130.40
Upside: -11.04%
Merck KGaA
Jul 20, 2026
Maintained: Buy
Price Target: €150.00
Current: €144.25
Upside: +3.99%
AstraZeneca PLC
Jul 13, 2026
Maintained: Buy
Price Target: 17,600p
Current: 13,108p
Upside: +34.27%
GSK plc
Jul 13, 2026
Maintained: Hold
Price Target: 1,940p
Current: 2,018p
Upside: -3.87%
Bayer Aktiengesellschaft
Jul 13, 2026
Maintained: Buy
Price Target: €52.00
Current: €47.03
Upside: +10.57%
Novo Nordisk A/S
Jul 13, 2026
Maintained: Hold
Price Target: kr 332.00
Current: kr 330.56
Upside: +0.44%
Sartorius Aktiengesellschaft
Jul 13, 2026
Maintained: Hold
Price Target: €240.00
Current: €222.40
Upside: +7.91%
Sartorius Stedim Biotech S.A.
Jul 13, 2026
Maintained: Hold
Price Target: €220.00
Current: €170.00
Upside: +29.41%
Sanofi
Jul 13, 2026
Maintained: Hold
Price Target: €88.00
Current: €79.38
Upside: +10.86%
May 13, 2026
Maintained: Buy
Price Target: CHF 376.00
Current: CHF 367.90
Upside: +2.20%
Nov 1, 2024
Maintained: Buy
Price Target: $125
Current: $131.82
Upside: n/a
Jan 27, 2022
Maintained: Buy
Price Target: CHF 750.00
Current: CHF 560.20
Upside: n/a
Feb 11, 2020
Upgraded: Hold
Price Target: €95.00 → €72.00
Current: €160.40
Upside: n/a
Nov 2, 2018
Maintained: Hold
Price Target: $310
Current: $50.96
Upside: n/a
Jul 5, 2017
Downgraded: Sell
Price Target: n/a
Current: $159.85
Upside: n/a